Clinical Review ABC of antithrombotic therapy

Bleeding risks of antithrombotic therapy

BMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7368.828 (Published 12 October 2002) Cite this as: BMJ 2002;325:828
  1. David A Fitzmaurice,
  2. Andrew D Blann,
  3. Gregory Y H Lip

    Many of the common cardiovascular disorders (especially in elderly people) are linked to thrombosis—such as ischaemic heart disease, atrial fibrillation, valve disease, hypertension, and atherosclerotic vascular disease—requiring the use of antithrombotic therapy. This raises questions regarding the appropriate use of antithrombotic therapy in older people, especially because strategies such as anticoagulation with warfarin need regular monitoring of the international normalised ratio (INR), a measure of the induced haemorrhagic tendency, and carry a risk of bleeding. The presence of concomitant physical and medical problems increases the interactions and risks associated with warfarin, and anticoagulation in elderly patients often needs an assessment of the overall risk:benefit ratio.

    Questions to ask when considering oral anticoagulation

    • Is there a definite indication (such as atrial fibrillation)?

    • Is there a high risk of bleeding or strong contraindication against anticoagulation?

    • Will concurrent medication or disease states increase bleeding risk or interfere with anticoagulation control?

    • Is drug compliance and attendance at anticoagulant clinic for monitoring likely to be a problem?

    • Will there be regular review of the patient, especially with regard to risks and benefits of anticoagulation?


    ISI=international sensitivity ratio. The mean normal prothrombin time is often generated from samples from local healthy subjects or a commercially available standard. The exact value of the ISI depends on the thromboplastin used in the prothrombin time method

    Physical frailty in elderly people may reduce access to anticoagulant clinics for INR monitoring. The decline in cognitive function in some elderly patients also may reduce compliance with anticoagulation and the appreciation of bleeding risks and drug interactions. However, in recent studies of anticoagulation in elderly people, no significant associations of anticoagulant control were found with age, sex, social circumstances, mobility, domicillary supervision of medication, or indications for anticoagulation.

    Warfarin

    Bleeding is the most serious and common complication of warfarin treatment. For any given patient, the potential benefit from prevention of …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe